Logo image of ANTX

AN2 THERAPEUTICS INC (ANTX) Stock Fundamental Analysis

NASDAQ:ANTX - Nasdaq - US0373261058 - Common Stock - Currency: USD

1.13  0 (0%)

After market: 1.1399 +0.01 (+0.88%)

Fundamental Rating

2

Taking everything into account, ANTX scores 2 out of 10 in our fundamental rating. ANTX was compared to 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ANTX as it has an excellent financial health rating, but there are worries on the profitability. ANTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ANTX has reported negative net income.
ANTX had a negative operating cash flow in the past year.
In the past 5 years ANTX always reported negative net income.
In the past 5 years ANTX always reported negative operating cash flow.
ANTX Yearly Net Income VS EBIT VS OCF VS FCFANTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ANTX has a worse Return On Assets (-62.13%) than 67.57% of its industry peers.
ANTX has a Return On Equity (-69.23%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -62.13%
ROE -69.23%
ROIC N/A
ROA(3y)-43.77%
ROA(5y)-115.8%
ROE(3y)-47.36%
ROE(5y)-156.43%
ROIC(3y)N/A
ROIC(5y)N/A
ANTX Yearly ROA, ROE, ROICANTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANTX Yearly Profit, Operating, Gross MarginsANTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ANTX has been increased compared to 1 year ago.
ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANTX Yearly Shares OutstandingANTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
ANTX Yearly Total Debt VS Total AssetsANTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

ANTX has an Altman-Z score of -1.93. This is a bad value and indicates that ANTX is not financially healthy and even has some risk of bankruptcy.
ANTX has a Altman-Z score of -1.93. This is comparable to the rest of the industry: ANTX outperforms 44.86% of its industry peers.
There is no outstanding debt for ANTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.93
ROIC/WACCN/A
WACCN/A
ANTX Yearly LT Debt VS Equity VS FCFANTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 9.75 indicates that ANTX has no problem at all paying its short term obligations.
The Current ratio of ANTX (9.75) is better than 81.62% of its industry peers.
A Quick Ratio of 9.75 indicates that ANTX has no problem at all paying its short term obligations.
ANTX has a better Quick ratio (9.75) than 81.62% of its industry peers.
Industry RankSector Rank
Current Ratio 9.75
Quick Ratio 9.75
ANTX Yearly Current Assets VS Current LiabilitesANTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

ANTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.47%, which is quite impressive.
EPS 1Y (TTM)31.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ANTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.08% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.03%
EPS Next 2Y27.07%
EPS Next 3Y17.45%
EPS Next 5Y9.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANTX Yearly Revenue VS EstimatesANTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 10M 20M 30M
ANTX Yearly EPS VS EstimatesANTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANTX Price Earnings VS Forward Price EarningsANTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANTX Per share dataANTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as ANTX's earnings are expected to grow with 17.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.07%
EPS Next 3Y17.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AN2 THERAPEUTICS INC

NASDAQ:ANTX (2/21/2025, 8:01:17 PM)

After market: 1.1399 +0.01 (+0.88%)

1.13

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)N/A N/A
Inst Owners54.94%
Inst Owner Change6.43%
Ins Owners9.35%
Ins Owner Change3.53%
Market Cap33.76M
Analysts50
Price Target2.72 (140.71%)
Short Float %0.25%
Short Ratio0.35
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.77%
Min EPS beat(2)10.87%
Max EPS beat(2)20.68%
EPS beat(4)4
Avg EPS beat(4)17.04%
Min EPS beat(4)10.87%
Max EPS beat(4)25.07%
EPS beat(8)6
Avg EPS beat(8)8.38%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-74.19%
PT rev (3m)-74.19%
EPS NQ rev (1m)0.49%
EPS NQ rev (3m)60.02%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.64%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB 0.39
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS0
BVpS2.93
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.13%
ROE -69.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.77%
ROA(5y)-115.8%
ROE(3y)-47.36%
ROE(5y)-156.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.75
Quick Ratio 9.75
Altman-Z -1.93
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.15%
EPS Next Y38.03%
EPS Next 2Y27.07%
EPS Next 3Y17.45%
EPS Next 5Y9.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-2.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-59.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-59.26%
OCF growth 3YN/A
OCF growth 5YN/A